Welcome to our dedicated page for McKesson SEC filings (Ticker: MCK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The McKesson Corporation (NYSE: MCK) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures filed with the U.S. Securities and Exchange Commission. These documents offer detailed information about McKesson’s healthcare services and pharmaceutical distribution activities, capital structure, governance, and financial reporting.
McKesson’s common stock and several series of notes, including 1.500% Notes due 2025, 1.625% Notes due 2026, and 3.125% Notes due 2029, are listed on the New York Stock Exchange, as shown in multiple Form 8-K filings. Filings such as Form 8-K report material events, including preliminary quarterly results, updated fiscal guidance, changes to reportable segments, and investor events like Investor Day. A Form 25 filing for 1.500% Notes due 2025 illustrates how specific debt securities can be removed from listing and registration on an exchange.
Investors can also review proxy materials, such as the definitive proxy statement (DEF 14A), which describes McKesson’s purpose, values, Board oversight, compensation matters, and shareholder voting results. These documents provide context on corporate governance, culture, and strategic priorities, including the company’s focus on North American pharmaceutical distribution, oncology and biopharma services platforms, and portfolio modernization.
On Stock Titan, SEC filings for MCK are updated from EDGAR and presented with AI-powered summaries designed to clarify key points in lengthy documents. Users can quickly identify the nature of each filing, from current reports on Form 8-K to proxy statements and other disclosures, and use AI-generated insights to understand segment changes, capital allocation decisions, and governance topics without reading every line of the underlying text.
This page is a useful starting point for reviewing McKesson’s regulatory history, tracking material events, and examining how the company communicates financial and strategic information through its SEC submissions.
McKesson Corp: Vanguard Capital Management reports beneficial ownership of 7.49% of common stock, equal to 9,180,981 shares as of 03/31/2026. The filing states Vanguard Capital Management exercises sole dispositive power over 9,180,981 shares and sole voting power for 1,220,257 shares. The holding includes securities held for Vanguard funds and managed accounts, described "in accordance with SEC Release No. 34-39538 (January 12, 1998)."
McKesson Corporation entered into a new senior unsecured revolving credit agreement providing a $5.0 billion credit line maturing in April 2031. This New Revolving Credit Facility replaces the company’s prior $1.0 billion 364‑day facility and $4.0 billion five‑year facility.
The facility includes a $4.5 billion sublimit for borrowings in Canadian Dollars, British Pound Sterling and Euros and a financial covenant capping total debt to Consolidated EBITDA at 4.25x, with a temporary step‑up to 4.75x after certain cash acquisitions of at least $500 million.
McKesson Corp executive Francisco Fraga filed an initial ownership report showing direct holdings of common stock and restricted stock units. As of April 1, 2026, he holds 3,464.417 shares of common stock directly, along with several RSU awards tied to McKesson common stock.
The RSUs cover 136, 398, 966 and 1,391 underlying shares, each vesting in thirds on specific dates from May 2024 through May 2028, reflecting multi-year equity compensation that delivers stock over time as service conditions are met.
McKesson Corporation disclosed that subsidiaries, led by McKesson Medical-Surgical Top Holdings, entered into new senior secured credit facilities totaling $2.0 billion. These include a $750.0 million Term Loan A-1 due 2031, a $250.0 million Term Loan A-2 due 2028, and a $1,000.0 million revolving credit facility maturing on April 1, 2031.
The term loans initially bear interest at the Adjusted Term SOFR Rate plus 1.250% per year, while revolving borrowings initially bear interest at the Term Benchmark Rate plus 1.250% or the Base Rate plus 0.250%, with margins later varying based on leverage and credit ratings. The facilities are secured by substantially all tangible and intangible assets of the borrower and certain U.S. subsidiaries and include customary covenants and financial tests on leverage and interest coverage.
McKesson Corp: The Vanguard Group filed Amendment No. 11 to a Schedule 13G/A reporting that, following an internal realignment, certain Vanguard subsidiaries will report beneficial ownership separately. The filing states amount beneficially owned: 0 shares and percent of class: 0% as of the amendment filing, and cites "SEC Release No. 34-39538 (January 12, 1998)" as the basis for disaggregation.
McKesson Corporation filed an 8‑K to share investor relations updates. The company will release its fourth quarter fiscal 2026 results after market close on May 7, 2026, followed by an earnings conference call and live webcast at 4:30 PM Eastern Time.
Chief Executive Officer Brian Tyler and Chief Financial Officer Britt Vitalone will host the call. McKesson also reaffirmed its fiscal 2026 full year outlook, consistent with guidance issued on February 4, 2026, and highlighted Mr. Vitalone’s participation in several major healthcare investor conferences, with webcasts available on its investor relations website.
McKesson Corporation announced a planned chief financial officer transition, with longtime CFO Britt J. Vitalone retiring and Kenny K. Cheung appointed as the new Executive Vice President and Chief Financial Officer.
Vitalone will step down as CFO on May 28, 2026, remain an employee through July 1, 2026, and then serve as a non‑employee advisor under an agreement providing a $50,000 monthly advisory fee. Cheung, age 44, joins from Sysco, where he was Executive Vice President and CFO, and previously held senior finance roles at Hertz, Nielsen and General Electric.
In connection with his appointment, Cheung will receive a one‑time $3,500,000 sign‑on cash bonus, sign‑on restricted stock units with a grant date value of $6,000,000, an annual base salary of $1,050,000, a target annual bonus opportunity equal to 125% of eligible earnings, performance stock units for the fiscal years 2027–2029 with a grant date value of $3,450,000, and additional restricted stock units with a grant date value of $2,300,000.
McKesson Corporation executive Michele Lau, EVP and Chief Legal Officer, reported an open-market sale of 2,725 shares of common stock at $990 per share on March 2, 2026, under a pre-arranged Rule 10b5-1 trading plan. After the sale, she directly holds 3,247 shares and indirectly holds 138.5939 shares through the McKesson Corporation 401(k) Retirement Savings Plan.
MCK filer files a Form 144 reporting a proposed sale of 2,725 common shares. The filing ties those shares to restricted stock vesting dated 02/09/2026 and lists the broker Fidelity Brokerage Services LLC on the NYSE. The filing also discloses that Michele Lau sold 303 common shares on 02/11/2026 for $282,817.17.
McKesson Corp director Maria Martinez sold shares in an open-market transaction. On this Form 4, she reported selling 349 shares of McKesson common stock on February 19, 2026 at an average price of $939.865 per share. After the sale, she directly owned 301 shares of McKesson common stock.